

Table 1 Therapy studies inclusive of acute, lymphoma, and progressing or poor prognosis chronic ATLL

<i>First author</i>	<i>Year</i>	<i>Therapy</i>	<i>Support</i>	<i>N</i>	<i>CR (%)</i>	<i>PR (%)</i>	<i>ALL (%)</i>	<i>Median survival (months)</i>	<i>Survival rate</i>
Lymphoma Study Group	1982	CHOP (VEPA) aka LSG-1			18			6.0	
Shimoyama, M	1988	VEPA v		54	17			6.0	4 years 8%
Tobinai	1994	VEPA-M (aka LSG-2) VEPA-B/M-FEPA/VEPP-B (aka LSG-4)			37 43			8.0	4 years 12%
Tsukasaki, K	1993	Combination chemotherapy (single institution cohort)		114	17.5	46.5	64		
Uozumi, K	1995	Response-orientated chemotherapy ?All treatment naïve		43	20.9	65.1	86	6.0	
Taguchi, H	1996	CHOP+ etoposide, vindesine, ranimustine and mitoxantrone	G-CSF	83	35.5	38.3	74.1	8.5	3 years 13.5%
Pawson, R	1998	Combination chemotherapy		21			63	5.5	
Matsushita, K	1999	OPEC/MPEC or etoposide/Pred (maintenance)		79	31	58.6	89.6	7.5	
Yamada, Y	2001	VCAP/AMP/VECP (JCOG9309/LSG-15) all treatment naïve	G-CSF	96	35.5	45.2	81	13.0	2 years 31%
Tsuda, H	1994	CPT-II, topoisomerase-I inhibitor (refractory disease)		13	7.7	30.1	38.8		
Ohno, R	1993	MST-16, topoisomerase-II inhibitor		24	8.33	25.0	33.3		
Tsukasaki, K	2003	VPA/etoposide+ deoxycoformycin aka LSG-11/JCOG9109		60	28	24	52	7.4	2 years 17%
Gill, P	1995	Interferon- α + zidovudine (half had refractory/relapsed disease)		19	26.3	31.5	57.8	3.0	
Hermine, O	1995	Interferon- α + zidovudine		18			66	10.0	
Matutes, E	2001	CHOP, interferon- α + zidovudine		15			67	18.0	
Hermine, O	2002	+/-CHOP, interferon- α + zidovudine		19	47	21	68	11.0	
Besson, C	2002	CHOP, interferon- α + zidovudine, etoposide		7				17.0	
Waldmann, T	1988	Anti-Tac antibody		19	11	21	33		
Waldmann, T	1995	90Y-labelled anti-Tac antibody		18	11	39	50		
Fukushima, T	2005	Allo-SCT		40	100			9.6	3 years 45.3%
<i>Acute ATLL only</i>									
Ohno, R	1993	MST-16, topoisomerase-II inhibitor		13	6.23	38.4	46.1		
Matsushita, K	1999	OPEC/MPEC or etoposide/Pred (maintenance)		51				6.7	
Yamada, Y	2001	VCAP/AMP/VECP	G-CSF	56	19.6	53.6	73.2	10.9	
Hermine, O	2002	+/-CHOP, interferon- α + zidovudine		15					
<i>Lymphoma only</i>									
Ohno, R	1993	MST-16, topoisomerase-II inhibitor		8	0	25.0	25.0		
Matsushita, K	1999	OPEC/MPEC or etoposide/Pred (maintenance)		22				9.6	
Yamada, Y	2001	VCAP/AMP/VECP	G-CSF	27	66.7	29.6	96.3	19.7	

Definitions of disease response (Yamada *et al.*, 2001): Complete remission – disappearance of all clinical and radiological evidence of disease and normalization of LDH for at least 4 weeks. Partial remission – greater than 50% reduction in disease for more than 4 weeks, and > 75% reduction in absolute abnormal lymphocyte counts, and LDH < 1.5 \times normal upper limit